Related references
Note: Only part of the references are listed.Novel Methods and Technologies for 21st-Century Clinical Trials A Review
E. Ray Dorsey et al.
JAMA NEUROLOGY (2015)
Performance of Nonlinear Mixed Effects Models in the Presence of Informative Dropout
Marcus A. Bjornsson et al.
AAPS JOURNAL (2015)
The Future Is Now: Model-Based Clinical Trial Design for Alzheimer's Disease
K. Romero et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Clinical evolution of Parkinson's disease and prognostic factors affecting motor progression: 9-year follow-up study
G. Reinoso et al.
EUROPEAN JOURNAL OF NEUROLOGY (2015)
Osteoarthritis Disease Progression Model Using Six Year Follow-up Data From the Osteoarthritis Initiative
Chaitali Passey et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Levodopa: Effect on Cell Death and the Natural History of Parkinson's Disease
C. Warren Olanow
MOVEMENT DISORDERS (2015)
Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression
Robert Kueffner et al.
NATURE BIOTECHNOLOGY (2015)
Disease duration and the integrity of the nigrostriatal system in Parkinson's disease
Jeffrey H. Kordower et al.
BRAIN (2013)
Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes
Mahesh N. Samtani et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development
P. A. Milligan et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Development of a placebo effect model combined with a dropout model for bipolar disorder
Wan Sun et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2013)
The Nature of Progression in Parkinson's Disease: An Application of Non-Linear, Multivariate, Longitudinal Random Effects Modelling
Lisa Kuramoto et al.
PLOS ONE (2013)
Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?
Anushree Chatterjee et al.
ANTIVIRAL THERAPY (2012)
Progression of motor and nonmotor features of Parkinson's disease and their response to treatment
Thuy C. Vu et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2012)
An Improved Model for Disease Progression in Patients From the Alzheimer's Disease Neuroimaging Initiative
Mahesh N. Samtani et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Combining patient-level and summary-level data for Alzheimer's disease modeling and simulation: a beta regression meta-analysis
James A. Rogers et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2012)
Design innovations and baseline findings in a long-term Parkinson's trial: The national institute of neurological disorders and stroke exploratory trials in Parkinson's Disease Long-Term Study-1
Jordan J. Elm
MOVEMENT DISORDERS (2012)
Bayesian Quantitative Disease-Drug-Trial Models for Parkinson's Disease to Guide Early Drug Development
Joo Yeon Lee et al.
AAPS JOURNAL (2011)
Nonlinear Decline of Mini-Mental State Examination in Parkinson's Disease
Dag Aarsland et al.
MOVEMENT DISORDERS (2011)
Interpreting the Results of Parkinson's Disease Clinical Trials: Time for a Change
Nick H. G. Holford et al.
MOVEMENT DISORDERS (2011)
Disease progression meta-analysis model in Alzheimer's disease
Kaori Ito et al.
ALZHEIMERS & DEMENTIA (2010)
Motor Complications in Parkinson's Disease: Ten Year Follow-Up Study
Iria Cabo Lopez et al.
MOVEMENT DISORDERS (2010)
Endpoints and Analyses to Discern Disease-Modifying Drug Effects in Early Parkinson's Disease
Venkatesh Atul Bhattaram et al.
AAPS JOURNAL (2009)
Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study
R. Nandhagopal et al.
BRAIN (2009)
Progression of Parkinson's disease in the clinical phase: potential markers
Walter Maetzler et al.
LANCET NEUROLOGY (2009)
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
C. Warren Olanow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The FDA critical path initiative and its influence on new drug development
Janet Woodcock et al.
ANNUAL REVIEW OF MEDICINE (2008)
Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions
Christopher G. Goetz et al.
MOVEMENT DISORDERS (2008)
Using disease progression models as a tool to detect drug effect
D. R. Mould et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Rate of clinical progression in Parkinson's disease. A prospective study
Anette Schrag et al.
MOVEMENT DISORDERS (2007)
Levodopa slows progression of Parkinson's disease. External validation by clinical trial simulation
Phylinda L. S. Chan et al.
PHARMACEUTICAL RESEARCH (2007)
Baseline cognitive function predicts rate of decline in basic-care abilities of individuals with dementia of the Alzheimer's type
Timothy B. Atchison et al.
ARCHIVES OF CLINICAL NEUROPSYCHOLOGY (2007)
Disease progression and pharmacodynamics in Parkinson disease - Evidence for functional protection with levodopa and other treatments
Nicholas H. G. Holford et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2006)
Selegiline slows the progression of the symptoms of Parkinson disease
S Pålhagen et al.
NEUROLOGY (2006)
Progression of motor impairment and disability in Parkinson disease - A population-based study
G Alves et al.
NEUROLOGY (2005)
Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials
P Guimaraes et al.
CLINICAL TRIALS (2005)
Modelling how ribavirin improves interferon response rates in hepatitis C virus infection
NM Dixit et al.
NATURE (2004)
Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: A randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial
I Shoulson et al.
ANNALS OF NEUROLOGY (2002)
Modelling viral and immune system dynamics
AS Perelson
NATURE REVIEWS IMMUNOLOGY (2002)
Placebo-associated improvements in motor function: Comparison of subjective and objective sections of the UPDRS in early Parkinson's disease
CG Goetz et al.
MOVEMENT DISORDERS (2002)
Pramipexole vs levodopa as initial treatment for Parkinson disease - A randomized controlled trial
R Holloway et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
Share Paper
